Methods to Estimate Willingness-to-Pay Per Quality Adjusted Life Year as Cost-Effectiveness Threshold

https://doi.org/10.22146/jmpf.33255

Tri Murti Andayani(1*), Dwi Endarti(2), Susi Ari Kristina(3), Rifqi Rokhman(4)

(1) Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada
(2) Department of Pharmaceutics, Faculty of Pharmacy, Universitas Gadjah Mada
(3) Department of Pharmaceutics, Faculty of Pharmacy, Universitas Gadjah Mada
(4) Department of Pharmaceutics, Faculty of Pharmacy, Universitas Gadjah Mada
(*) Corresponding Author

Abstract


Pharmacoeconomic studies, especially the cost-utility analysis method, require a cost-effectiveness threshold for interpretation of the cost-effectiveness ratios of the study. The cost-effectiveness threshold is determined by each country. Therefore, a study to determine the Willingness-To-Pay per Quality Adjusted Life Year (WTP per QALY) as cost effectiveness threshold for pharmacoeconomic studies is indispensable in Indonesia. The purpose of this study is to review the literature and to develop guidelines for estimating WTP per QALY as cost effectiveness threshold in pharmacoeconomic studies. Literature review was conducted using some electronic databases, such as MEDLINE, Pubmed, Science Direct, and Google Scholar. The study was conducted by holding survey on healthy population or patients. Estimated WTP per QALY are differentiated based on therapy for preventive, curative, and life saving or interventions that can prolong life expectancy. The study was conducted in three stages: measuring utility, measuring WTP, and combining WTP and utility values in WTP per QALY. Utility measurements are performed either with single or multi-attribute instruments, whereas WTP measurements use contingent valuation or discrete methods. Survey technique can be done with face to face interview, telephone, and internet. This research can be used as a guide in the development of methods to estimate WTP per QALY as cost effectiveness threshold in pharmacoeconomic studies.

Keywords


Cost-effectiveness threshold; literature review; pharmacoeconomics; WTP per QALY

Full Text:

PDF


References

Dranitsaris G. A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: An assessment of amifostine cytoprotection. Support Care Cancer. 1997;5(6):489-499. doi:10.1007/s005200050118.

Eichler HG, Kong SX, Gerth WC, Mavros P, Jönsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: How are cost-effectiveness thresholds expected to emerge? Value Heal. 2004;7(5):518-528. doi:10.1111/j.1524-4733.2004.75003.x.

FAO. Applications of the contingent valuation method in developing countries: A Survey. FAO Econ Soc Dev Pap. 2000;146.

Frew EJ, Wolstenholme JL, Whynes DK. Comparing willingness-to-pay: Bidding game format versus open-ended and payment scale formats. Health Policy (New York). 2004;68(3):289-298. doi:10.1016/j.healthpol.2003.10.003.

King JT, Tsevat J, Lave JR, Roberts MS. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Making. 2005;25(6):667-677. doi:10.1177/0272989X05282640.

Klose T. A utility-theoretic model for QALYs and willingness to pay. Health Econ. 2003;12(1):17-31. doi:10.1002/hec.697.

Martín-Fernández J, Polentinos-Castro E, del Cura-González MI, et al. Willingness to pay for a quality-adjusted life year: an evaluation of attitudes towards risk and preferences. BMC Health Serv Res. 2014;14(1):287. doi:10.1186/1472-6963-14-287.

Nimdet K, Ngorsuraches S. Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand. BMJ Open. 2015;5(10):e008123. doi:10.1136/bmjopen-2015-008123.

Paul Revill JO, James Lomas RN, Beth Woods, Alex Rollinger MS, Mark Sculpher KC. Cost-Effectiveness Threshold: Guiding Health Care Spending for Population Health Improvement.; 2015.

Pinto-Prades JL, Loomes G, Brey R. Trying to estimate a monetary value for the QALY. J Health Econ. 2009;28(3):553-562. doi:10.1016/j.jhealeco.2009.02.003.

Pinto-Prades JL, Sánchez-Martínez FI, Corbacho B, Baker R. Valuing QALYs at the end of life. Soc Sci Med. 2014;113:5-14. doi:10.1016/j.socscimed.2014.04.039.

Thavorncharoensap M, Teerawattananon Y, Natanant S, Kulpeng W, Yothasamut J, Werayingyong P. Estimating the willingness to pay for a quality- adjusted life year in Thailand: Does the context of health gain matter? Clin Outcomes Res. 2013;5(1):29-36. doi:10.2147/CEOR.S38062

Zhao FL, Yue M, Yang H, Wang T, Wu JH, Li SC. Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making?: results from a study in patients with chronic prostatitis. Med Care. 2011;49:267-272. doi:10.1097/MLR.0b013e31820192cd.



DOI: https://doi.org/10.22146/jmpf.33255

Article Metrics

Abstract views : 2564 | views : 5941

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

©Jurnal Manajemen dan Pelayanan Farmasi
Faculty of Pharmacy
Universitas Gadjah Mada
Creative Commons License
View My Stats